MEXT Science and Technology/Academic Policy Bureau Visits Craif Research Lab
On May 28, 2026, MEXT official Atsushi Oku visited Craif's research lab at Nagoya University to observe its bio-AI analysis technology for the MiSignal urine cancer risk test and its automated lab environment.
📋 Article Processing Timeline
- 📰 Published: June 5, 2026 at 10:00
- 🔍 Collected: June 5, 2026 at 10:26 (26 min after Published)
- 🤖 AI Analyzed: June 6, 2026 at 20:12 (33h 46m after Collected)
Bio-AI startup Craif Inc. hosted MEXT official Atsushi Oku and his delegation at its research lab inside Nagoya University on May 28, 2026. The visitors observed the automated lab environment and Craif's bio-AI analysis technology used in its urine-based cancer risk screening test, MiSignal.
Located in the Nagoya University NIC building, Craif's laboratory acts as a data hub, analyzing over 50,000 urine samples gathered via joint research with over 50 university hospitals and cancer centers. The lab utilizes a proprietary digital clinical lab system that automates sample management and measurement to minimize human error and ensure stable, high-throughput operations.
Its screening service, MiSignal Scan (not a medical device), evaluates the risk of 10 cancer types, including pancreatic cancer, from Stage 1 by using AI to analyze urinary microRNA. Founded in 2018, Craif leverages its NANO IP (NANO Intelligence Platform) and AI technologies to develop non-invasive early cancer detection tests, aiming to help people live healthy, long lives.
Located in the Nagoya University NIC building, Craif's laboratory acts as a data hub, analyzing over 50,000 urine samples gathered via joint research with over 50 university hospitals and cancer centers. The lab utilizes a proprietary digital clinical lab system that automates sample management and measurement to minimize human error and ensure stable, high-throughput operations.
Its screening service, MiSignal Scan (not a medical device), evaluates the risk of 10 cancer types, including pancreatic cancer, from Stage 1 by using AI to analyze urinary microRNA. Founded in 2018, Craif leverages its NANO IP (NANO Intelligence Platform) and AI technologies to develop non-invasive early cancer detection tests, aiming to help people live healthy, long lives.
FAQ
Who from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) visited Craif's research lab?
Mr. Atsushi Oku, Director of the Human Resources Policy Division of the Science and Technology/Academic Policy Bureau, along with other MEXT officials.
When did the visit take place?
Thursday, May 28, 2026.
Where is Craif's research lab located?
Inside the NIC Building on the Nagoya University campus.
What is "MySignal-Scan"?
It is a non-invasive test that evaluates the risks of 10 types of cancer, including pancreatic cancer, individually from Stage 1 by extracting microRNA from urine and analyzing it with AI.
What is the price of "MySignal-Scan"?
No price information is provided in the press release.